| abstract |
The present invention discloses a cytotoxic cocktail comprising: (a) a therapeutically effective amount of at least one cannabinoid selected from the group consisting of: cannabidiol (CBD) or a derivative thereof, Tetrahydrocannabinol (THC) or a derivative thereof, and any combination thereof; and (b) at least one therapeutic agent selected from the group consisting of: bortezomib (BTZ), carfilzomib (CFZ), lenalidomide (LEN), dexamethasone (DEX), melphalan (MEL) and doxorubicin (DOXO). In a core embodiment the cocktail is conferring a synergistic effect with respect to inhibition or cytotoxicity of multiple myeloma (MM) cells, relative to said at least one therapeutic agent selected from the group consisting of: BTZ, CFZ, LEN, DEX, MEL, DOXO and said CBD and THC, administered separately in a similar concentration. |